Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 17 articles:
HTML format
Text format



Single Articles


    May 2017
  1. XU YL, Yao R, Li J, Zhou YD, et al
    FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2017 May 10. doi: 10.1007/s00280-017-3319.
    PubMed     Text format     Abstract available


    April 2017
  2. MOUSAVI E, Tavakolfar S, Almasirad A, Kooshafar Z, et al
    In vitro and in vivo assessments of two novel hydrazide compounds against breast cancer as well as mammary tumor cells.
    Cancer Chemother Pharmacol. 2017 Apr 27. doi: 10.1007/s00280-017-3318.
    PubMed     Text format     Abstract available


  3. REN YQ, Wang HJ, Zhang YQ, Liu YB, et al
    WBP2 modulates G1/S transition in ER+ breast cancer cells and is a direct target of miR-206.
    Cancer Chemother Pharmacol. 2017 Apr 8. doi: 10.1007/s00280-017-3302.
    PubMed     Text format     Abstract available


    March 2017
  4. CHE J, Huang Y, Xu C, Zhang P, et al
    Increased ceramide production sensitizes breast cancer cell response to chemotherapy.
    Cancer Chemother Pharmacol. 2017 Mar 29. doi: 10.1007/s00280-017-3292.
    PubMed     Text format     Abstract available


  5. ROCCA A, Cecconetto L, Passardi A, Melegari E, et al
    Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3279.
    PubMed     Text format     Abstract available


  6. TANDIA M, Mhiri A, Paule B, Saffroy R, et al
    Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3268.
    PubMed     Text format     Abstract available


    February 2017
  7. WANG Z, Chen J, Zhong MZ, Huang J, et al
    Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
    Cancer Chemother Pharmacol. 2017 Feb 27. doi: 10.1007/s00280-017-3248.
    PubMed     Text format     Abstract available


  8. KONG X
    Reply to: comment on "Meta-analysis of GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer".
    Cancer Chemother Pharmacol. 2017 Feb 22. doi: 10.1007/s00280-016-3230.
    PubMed     Text format    


    January 2017
  9. QUARTINO AL, Li H, Jin JY, Wada DR, et al
    Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
    Cancer Chemother Pharmacol. 2017 Jan 10. doi: 10.1007/s00280-016-3218.
    PubMed     Text format     Abstract available


  10. ZHANG HY, Liang F, Zhang JW, Wang F, et al
    Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3208.
    PubMed     Text format     Abstract available


  11. CARGNIN S, Terrazzino S
    Comment to: GSTP1, GSTM1 and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 Jan 6. doi: 10.1007/s00280-016-3229.
    PubMed     Text format    


    October 2016
  12. KONG X, Li Z, Li X
    GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  13. SONG JG, Lee YS, Park JA, Lee EH, et al
    Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  14. PARK JH, Kang MJ, Ahn JH, Kim JE, et al
    Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change afte
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  15. ZHANG X, Bai W
    Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  16. LI C, Wang B, Lu D, Jin JY, et al
    Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  17. YOSHITOMI S, Taira N, Doihara H, Mizoo T, et al
    A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: